Growth Beats, Margins Crack: A Transformation in Motion but Execution Unproven
Pajson beat revenue guidance by 3 points but missed margin recovery by over 100 basis points. The quarter reveals a company scaling fast into a global franchise—but quality of earnings is softening, and institutions are trimming.
₹143.4 Cr
+23% YoY vs 20% guidance
14%
vs 15–16% prior target
95%
vs 86% prior year
37.5%
up from 34% YoY
The headline says Pajson beat growth guidance—23% revenue versus the prior 20% steer. But step behind that: EBITDA margins fell to 14%, undershooting the 15–16% recovery target that management promised. The real story is not the beat; it's the quality miss. A company absorbing 95% of its existing 18k MT capacity while scaling institutional business to 37.5% of revenue is doing real work. But it's doing it in a margin vice: forex headwinds, freight surcharged, raw cashew prices stubborn. Management is clear-eyed about it, but didn't revise guidance downward or articulate a recovery path—and institutions have begun trimming.
Where the margin compression came from
EBITDA fell from 18% in prior-year H1 to 12–13% in current H1, per management disclosures. That 500+ basis point swing is not operational delinquency—it's macro. Plant was running at 95% utilization, the highest in the company's covered history. The issue: input costs remained elevated, forex moved adverse, and freight surcharged. Management chose to hold volume and customer relationships rather than price aggressively, which left the margin to absorb the shock. This is operationally sound but financially painful, and it means FY27's margin recovery (the prior guidance promise) now sits in question.
H1 FY27 revenue up 23% YoY to ₹145 Cr
SupportedDelivered ₹143.4 Cr; H1 aggregate consistent with 23% claim
EBITDA margins 14% in H1, recovery on track
Overstated14% actual vs 15–16% prior guidance; margin fell vs. FY26 H2
PAT ₹12.6 Cr, 19% growth vs. H2 prior year
SupportedDelivered PAT ₹12.6 Cr exactly; growth rate verified
95% plant utilization vs 86% prior year
SupportedStrong efficiency gains despite cost headwinds
Institutional revenue 37.5% vs 34% prior year
SupportedChannel mix improving; large food/snack conglomerates showing traction
What changed on this call
Margin guidance tacitly abandoned—no FY28 reconfirmation or revision announced
Pacific Global acquisition (60k MT Africa, share-swap) approved and transformational
Institutional channel jumped to 37.5% from 34%, 178 distributors across 20+ states
Vizianagaram greenfield delayed 45 days (cyclones); now targeting Feb or Q4 FY27 trials
Royal Mewa consumer brand grew from 1.36% to 4.6% of revenue; targeting 15% in 3–5 years
The market's own verdict
Pajson trades at ₹340 on a bullish trend—above its 20-, 50-, and 200-day moving averages (₹314.64, ₹271.18, and ₹208.67 respectively). The stock is up 183% off its 52-week low but sits -17% below its all-time high of ₹411.4, suggesting profit-taking from the peak. RSI of 62 is neutral—not overbought, not oversold. But ownership tells a different story: FII holdings collapsed from 0.92% to 0.00% quarter-on-quarter, and DII reduced from 10.95% to 7.63%. Promoter holding steady at 62.47%. The stock is up sharply, but institutions are trimming on the back of the result. That's a red flag: the market has already priced the bull case and is now skeptical on execution and margin recovery.
Bull-bear ledger
Revenue beat guidance by 300 bps—institutional channel at 37.5% is recurring, diversified
95% plant utilization despite macro headwinds shows operational excellence
113k MT combined capacity (India 18k + Vizianagaram 35k + Pacific Global 60k) by FY28 is transformational
Pacific Global origin-processing advantage (5–7% higher EBITDA vs India) structural tailwind
Management committed to 5–8% global cashew market share in 5–7 years with quantified roadmap
Margin guidance missed (14% vs 15–16%), tacitly abandoned, no recovery path articulated
Management declined FY28 EBITDA numbers—unusual caution for a call with strong operational disclosure
Vizianagaram already 45 days late due to cyclones; further delays risk FY28 ramp targets
FII/DII both trimming despite stock near ATH; institutions vote of no confidence on execution
Acquisition integration unproven; working capital will rise; cross-geography controls nascent
Geopolitical forex volatility described as 'unprecedented'; hedging costs unquantified
Risks, ranked by how much they should concern a holder
Margin recovery target abandoned; no FY28 EBITDA path
HighEarnings quality is softening despite 95% utilization. If margins stay at 12–13% through FY27–FY28, the case becomes growth-at-cost, not value creation.
Geopolitical forex volatility unprecedented; unhedged exposure
HighManagement cited 'unprecedented' pressure; INR weakness and commodity currency swings are macro tails not in their control. Hedging costs eat margins further.
Vizianagaram commissioning delays sequential
Medium-HighAlready 45 days late; further slippage post Feb/Q4 FY27 risk delays the 113k MT capacity target and FY28 margin uplift. Execution credibility stakes are high.
Pacific Global integration and working capital surge
MediumShare-swap acquisition; minority governance unproven; farm-to-fork model will balloon working capital. Integration hiccups = cash drain, margin dilution.
Input-cost inflation persistent; pricing power constrained
MediumRaw cashew prices remain elevated; management held volume over price. If input costs don't fall, margins stay capped and pricing power stays absent.
Concentrated African sourcing; geopolitical supply risk
MediumIvory Coast (Cote d'Ivoire) is world's largest raw cashew supplier but geopolitically volatile. Sourcing disruption = supply shock; Pacific Global is greenfield, untested.
The debate
What to watch next
1 · Vizianagaram facility trials by Feb / Q4 FY27
The first real execution gate. Any further delays beyond Feb signal project risk. Timely commissioning is the linchpin for the 113k MT thesis and FY28 margin recovery.
2 · Pacific Global consolidation and first African earnings (Jan–Feb FY27)
Integration progress, working capital impact, and first consolidated financials will show whether the 5–7% margin uplift thesis is real or aspirational. Governance and cross-geography controls matter here.
3 · Q3 FY27 margin inflection
Will margins stay compressed at 12–13% or recover toward 15–16%? This is the single most important data point. If margins haven't recovered by Q3 (or management hasn't revised guidance), the hold becomes a sell.
Pajson is a transformation story that needs to prove itself. Revenue is beating, institutional channels are real, and the global pivot via Pacific Global is bold. But margin trends are worsening, not improving—management is cautious on forward numbers and has tacitly abandoned prior margin guidance—and institutions are already trimming. The stock is up 83% off its low but -17% from the peak; that's the market repricing risk.
Hold if you own for the long thesis, but watch the three catalysts closely. The single number to track is H2 / Q3 EBITDA margin. If it recovers toward 15–16% by Q3, the case re-rates higher. If it stays at 12–13%, the transformation is costlier than advertised, and re-rating comes only when Africa adds scale. This is a 2–3 year view, not a quick trade.
Informational and educational content only. Not investment advice.